Eli Lilly (LLY)
1,152.54
-29.33 (-2.48%)
NYSE· Last Trade: Jul 14th, 7:20 PM EDT
Detailed Quote
| Previous Close | 1,181.87 |
|---|---|
| Open | 1,166.01 |
| Bid | 1,154.50 |
| Ask | 1,156.43 |
| Day's Range | 1,140.74 - 1,166.01 |
| 52 Week Range | 623.78 - 1,249.45 |
| Volume | 2,640,892 |
| Market Cap | 1.10T |
| PE Ratio (TTM) | 50.22 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.60%) |
| 1 Month Average Volume | 3,105,990 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over 18 months.
Via Investor's Business Daily · July 14, 2026
Eyes are on the rollout of Lilly's new weight loss pill.
Via The Motley Fool · July 14, 2026
Eli Lilly & Co. (NYSE:LLY) Passes Navellier’s High-Growth Screen on Strong Earnings and Sales Momentumchartmill.com
Via Chartmill · July 14, 2026
Cathie Wood's ARK Invest was extremely active last week, adding SpaceX and Meta, while selling AMD and Robinhood stock.
Via Investor's Business Daily · July 13, 2026
Eli Lilly shares are in the spotlight Monday as the company presents new Kisunla data at the AAIC in London.
Via Benzinga · July 13, 2026
Two drugs now generate almost two-thirds of the pharmaceutical giant's revenue.
Via The Motley Fool · July 13, 2026
IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.
Via The Motley Fool · July 11, 2026
BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield.
Via The Motley Fool · July 11, 2026
One small investment offers big benefits for Nvidia.
Via The Motley Fool · July 11, 2026
This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.
Via The Motley Fool · July 11, 2026
There are good reasons to invest in Lilly and to hold off.
Via The Motley Fool · July 11, 2026
It's something very simple.
Via The Motley Fool · July 11, 2026
So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.
Via The Motley Fool · July 10, 2026
Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.
Via The Motley Fool · July 10, 2026
Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.
Via The Motley Fool · July 9, 2026
PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at lower cost.
Via The Motley Fool · July 9, 2026
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
Via The Motley Fool · July 9, 2026
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Via StockStory · July 9, 2026
Investing for the long-term requires a different strategy.
Via The Motley Fool · July 8, 2026
PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost.
Via The Motley Fool · July 8, 2026
The stock has soared 400% in recent years.
Via The Motley Fool · July 8, 2026
As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.
Via MarketBeat · July 8, 2026
Check out the companies making headlines yesterday: Carlisle (NYSE:CSL): Building envelope solutions provider Carlisle Companies (NYSE:CSL) fell by 4.2% on T...
Via StockStory · July 8, 2026
Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them.
Via The Motley Fool · July 8, 2026
Wall Street is getting more bullish on the pharma giant's shares.
Via The Motley Fool · July 7, 2026